Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Interest & Investment Income (2016 - 2025)

Celldex Therapeutics (CLDX) has 14 years of Interest & Investment Income data on record, last reported at $5.8 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 34.68% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $28.6 million, down 23.12%, while the annual FY2025 figure was $28.6 million, 23.12% down from the prior year.
  • Interest & Investment Income reached $5.8 million in Q4 2025 per CLDX's latest filing, down from $6.6 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $10.5 million in Q2 2024 and bottomed at $66000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $4.1 million, with a median of $3.0 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: tumbled 90.06% in 2021, then surged 1402.42% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $193000.0 in 2021, then skyrocketed by 624.35% to $1.4 million in 2022, then soared by 209.08% to $4.3 million in 2023, then surged by 106.78% to $8.9 million in 2024, then plummeted by 34.68% to $5.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $5.8 million in Q4 2025, $6.6 million in Q3 2025, and $7.3 million in Q2 2025.